InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.005 0.002 (66.67%)+
Announcement
Release
31 Jul 2026 8:29AM
Price at Release
$0.003
Full Release
download
Summary
Percheron Therapeutics Limited, an Australian biotechnology company, provided an update on their activities for the quarter ending 30 June 2026. The company focuses on developing therapies for oncology and rare diseases, with their lead program being HMBD-002, a monoclonal antibody targeting the VISTA immune checkpoint regulator. Key achievements include receiving the provisional International Non-Proprietary Name 'minperstobart' for HMBD-002, completing the manufacture of a new batch of the drug substance, and raising $2.2 million through a non-renounceable entitlement offer to fund further clinical trials. The company presented scientific data at major conferences, showing HMBD-002 to be safe and well-tolerated. Financially, they reported a cash balance of $4.05 million, with net cash outflows from operations amounting to $1.05 million.
Key Points
  • HMBD-002 granted pINN 'minperstobart' by WHO
  • Completion of new drug substance batch for HMBD-002
  • Raised $2.2 million through a non-renounceable entitlement offer
  • Presented HMBD-002 data at AACR and ASCO conferences
  • Reported net cash outflows of $1.05 million for the quarter
  • Cash balance at quarter end was $4.05 million
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.